Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Fineline Cube Jan 4, 2026
Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Policy / Regulatory

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Fineline Cube Jan 4, 2026
Company Deals

CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments

Fineline Cube Jun 16, 2025

China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...

Company Deals

Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development

Fineline Cube Jun 16, 2025

Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...

Company Deals

Nona Biosciences Licenses HCAb Technology to Visterra for Biologic Development

Fineline Cube Jun 13, 2025

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with...

Company Deals

BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies

Fineline Cube Jun 13, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...

Company Drug

AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults

Fineline Cube Jun 13, 2025

US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...

Company Drug

Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment

Fineline Cube Jun 13, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...

Company Deals

GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries

Fineline Cube Jun 13, 2025

UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an...

Company Drug

Merck Launches Phase III Trial for Quadrivalent Dengue Vaccine V181

Fineline Cube Jun 13, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III...

Company Deals

NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery

Fineline Cube Jun 13, 2025

US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo...

Company Drug

Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial

Fineline Cube Jun 13, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced positive results from a Phase II study of...

Company Deals

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research

Fineline Cube Jun 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a...

Company Deals

Bayzed Health Launches HK IPO to Expand Cancer Care Services

Fineline Cube Jun 13, 2025

China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...

Company Deals

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share

Fineline Cube Jun 13, 2025

China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...

Company Drug

BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications

Fineline Cube Jun 13, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals Medical Device

Gene Solutions Partners with Topgen Biopharm to Advance Precision Oncology in Asia

Fineline Cube Jun 13, 2025

Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s...

Company Deals

Suzhou’s MEI Medical Secures RMB 100M Funding for ePTFE Innovation

Fineline Cube Jun 13, 2025

Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention,...

Company Drug

BMS Reports Positive POETYK PsA-1 Results for Sotyktu in Psoriatic Arthritis

Fineline Cube Jun 13, 2025

US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...

Company Drug

Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management

Fineline Cube Jun 13, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...

Company Deals

XtalPi Acquires Liverpool ChiroChem to Boost AI-Driven Drug Discovery

Fineline Cube Jun 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of...

Company Deals

Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug

Fineline Cube Jun 12, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...

Posts pagination

1 … 82 83 84 … 603

Recent updates

  • Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
  • China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
  • China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
  • Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
  • Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.